Literature DB >> 9815582

Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.

M Engelhardt1, P Drullinsky, J Guillem, M A Moore.   

Abstract

Telomerase and telomere length are increasingly studied as prognostic markers in malignancy. Telomerase is also known to be expressed in certain nonmalignant cells, although generally at low levels. We investigated telomerase activity and telomere length in premalignant, malignant, inflammatory, and normal colon specimens to determine whether significant differences exist and whether telomerase may serve as a marker for early- or late-stage colorectal cancer. Telomerase activity was evaluated in 130 frozen specimens from human colon cancer (n = 50), adjacent normal colon tissue (n = 50), colon polyps (n = 20), and colitis (n = 10) using a modified telomeric repeat amplification protocol assay, and telomere length was assessed by terminal restriction fragment analysis. High to moderate levels of telomerase activity were detected in 90% of colorectal tumors. Weakly positive activity was detected in 10%. None of the normal tissues exhibited telomerase activity. In polyps and colitis, telomerase activity was found in 60% (12 of 20) and 40% (4 of 10), respectively. Telomerase activity in both nonmalignant lesions was 25- to 54-fold lower than that detected in colon cancer (P < 0.001). We found a positive correlation between tumor cell infiltration determined in cryostat sections and telomerase activity (r = 0.886; P > 0.0001). Late-stage tumors (Dukes C + D) demonstrated increased telomerase activity compared to early-stage tumors (Dukes A + B). Telomere restriction fragments in colon tumors had peak values of 4.8 +/- 1 kbp that were significantly and consistently shorter than those of the adjacent normal tissues (7.54 +/- 1.3 kbp), polyps (7.5 +/- 0.7 kbp), and colitis specimens (7.7 +/- 0.5kbp; P < 0.0001). Telomeres were 0.6 kbp longer in tumors with high telomerase activity and in late-stage cancers (Dukes C + D) compared to those in tumors with low telomerase activity and in early-stage cancers (Dukes A + B). Our data demonstrate that telomerase in colon cancer was commonly acquired, and activity was higher than that in polyps and colitis. However, weak telomerase activity was detected in premalignant and inflammatory lesions. Telomeres in colon cancer were considerably shorter, an indication of extensive cell proliferation and population divisions, whereas adjacent normal colon specimens, polyps, and colitis had comparable telomere lengths. Our results indicate that increased telomerase activity occurs in colon cancer cells that have undergone extensive telomere shortening relative to surrounding normal tissues and in which telomerase-induced stabilization of telomeres may be critical for the continued proliferation of the malignant clone. The link between telomerase activity and stage suggests that telomerase is up-regulated as a function of increased tumor cell invasion, tumor progression, and metastatic potential in colon cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815582

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  61 in total

1.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence.

Authors:  Xin Zhou; Alan K Meeker; Kepher H Makambi; Ourania Kosti; Bhaskar V S Kallakury; Mary K Sidawy; Christopher A Loffredo; Yun-Ling Zheng
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

3.  Zinc deficiency or excess within the physiological range increases genome instability and cytotoxicity, respectively, in human oral keratinocyte cells.

Authors:  Razinah Sharif; Philip Thomas; Peter Zalewski; Michael Fenech
Journal:  Genes Nutr       Date:  2011-09-21       Impact factor: 5.523

Review 4.  Assessing cell and organ senescence biomarkers.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

5.  Determining if telomeres matter in colon cancer initiation or progression.

Authors:  Jerry W Shay
Journal:  J Natl Cancer Inst       Date:  2013-08-05       Impact factor: 13.506

6.  The relationship between telomere length and clinicopathologic characteristics in colorectal cancers among Tunisian patients.

Authors:  Raja Mzahma; Maher Kharrat; Fadhel Fetiriche; Mounir Ben Moussa; Zoubeir Ben Safta; Chadli Dziri; AbdelJelil Zaouche; Habiba Chaabouni-Bouhamed
Journal:  Tumour Biol       Date:  2015-06-06

Review 7.  Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.

Authors:  Paula Martínez; María A Blasco
Journal:  Nat Rev Cancer       Date:  2011-03       Impact factor: 60.716

Review 8.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

9.  Mean leukocyte telomere length and risk of incident colorectal carcinoma in women: a prospective, nested case-control study.

Authors:  I-Min Lee; Jennifer Lin; Amy J Castonguay; Nathaniel S Barton; Julie E Buring; Robert Y L Zee
Journal:  Clin Chem Lab Med       Date:  2010-02       Impact factor: 3.694

10.  Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers.

Authors:  E Rampazzo; R Bertorelle; L Serra; L Terrin; C Candiotto; S Pucciarelli; P Del Bianco; D Nitti; A De Rossi
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.